Spectrum Pharmaceuticals, Inc. (SPPI) – Financial and Strategic SWOT Analysis Review

Spectrum Pharmaceuticals, Inc. (SPPI) – Financial and Strategic SWOT Analysis Review Cover

Single Licence: $125

Buy Now
customer(s) bought this report
BUY WITH CONFIDENCE

Shopping on CFDMaster.com is Safe and Secure. GUARANTEED!
All information is encrypted and handled by PayPal.com

Need Assistance?
Have you got questions about this report? Why not speak to one of our advisors. Email us at business@cfdmaster.com or call us at +61 (02) 8011 3208
# Pages
Market
Country
Single User
Site License
Enterprisewide
49
Pharmaceuticals and Healthcare
United States

Spectrum Pharmaceuticals, Inc. (SPPI) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

– Business description – A detailed description of the company’s operations and business divisions.
– Corporate strategy – Analyst’s summarization of the company’s business strategy.
– SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
– Company history – Progression of key events associated with the company.
– Major products and services – A list of major products, services and brands of the company.
– Key competitors – A list of key competitors to the company.
– Key employees – A list of the key executives of the company.
– Executive biographies – A brief summary of the executives’ employment history.
– Key operational heads – A list of personnel heading key departments/functions.
– Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
– Key manufacturing facilities – A list of key manufacturing facilities of the company.
– Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
– Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Spectrum Pharmaceuticals, Inc., (Spectrum Pharmaceuticals), formerly, NeoTherapeutics, Inc., is an integrated biotechnology company. It carries out the acquisition, development, and commercialization of diverse pipeline of late-stage clinical and commercial products with particular focus on oncology. The company markets four drugs, namely, Fusilev, Folotyn, Zevalin and Marqibo. It has three drugs in late stage development, namely, apaziquone, belinostat and Captisol-enabled Melphalan also has a diversified pipeline of novel drug candidates for various therapeutic categories.

Spectrum Pharmaceuticals, Inc. Key Recent Developments

Mar 13, 2015 Spectrum Pharmaceuticals Reports Robust Clinical Data and Strong 2014 Financial Results
Nov 06, 2014 Spectrum Pharmaceuticals Reports Strong Product Sales for the Third Quarter 2014; Sales of $47.9 Million up 15.6% Over Last Year
Aug 07, 2014 Spectrum Pharmaceuticals Reports 45% Sales Growth in the Second Quarter, Launches Fifth Product and Moves Closer to a Decision on a Potential Blockbuster
May 08, 2014 Spectrum Pharmaceuticals Reports Financial Results for First Quarter 2014

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
– The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
– The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
– Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
– Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
– Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company



Table of Contents

Section 1 – About the Company 6
Spectrum Pharmaceuticals, Inc. – Key Facts 6
Spectrum Pharmaceuticals, Inc. – Key Employees 7
Spectrum Pharmaceuticals, Inc. – Key Employee Biographies 8
Spectrum Pharmaceuticals, Inc. – Major Products and Services 9
Spectrum Pharmaceuticals, Inc. – Pharmaceutical Pipeline Products Data 10
Spectrum Pharmaceuticals, Inc., Pipeline Products by Therapy Area 10
Spectrum Pharmaceuticals, Inc., Pipeline Products by Development Phase 11
Spectrum Pharmaceuticals, Inc. – History 14
Spectrum Pharmaceuticals, Inc. – Company Statement 18
Spectrum Pharmaceuticals, Inc. – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Section 2 – Company Analysis 21
Spectrum Pharmaceuticals, Inc. – Business Description 21
Spectrum Pharmaceuticals, Inc. – Corporate Strategy 22
Spectrum Pharmaceuticals, Inc. – SWOT Analysis 23
SWOT Analysis – Overview 23
Spectrum Pharmaceuticals, Inc. – Strengths 23
Strength – Patents and Proprietary Technology Portfolio 23
Strength – Strong Liquidity Position 23
Strength – Robust Product Portfolio 23
Spectrum Pharmaceuticals, Inc. – Weaknesses 24
Weakness – Dependence on Suppliers 24
Weakness – Operational Inefficiency 24
Weakness – Limited Number of Customers 24
Spectrum Pharmaceuticals, Inc. – Opportunities 25
Opportunity – Key Business Initiatives 25
Opportunity – Growing Cancer Market 25
Opportunity – Portfolio of Pipeline Products 25
Spectrum Pharmaceuticals, Inc. – Threats 26
Threat – Government Regulations 26
Threat – Intense Competition 26
Threat – Technological Changes 26
Spectrum Pharmaceuticals, Inc. – Key Competitors 27
Section 3 – Company Financial Ratios 28
Financial Ratios – Capital Market Ratios 28
Financial Ratios – Annual Ratios 29
Performance Chart 31
Financial Performance 31
Financial Ratios – Interim Ratios 32
Financial Ratios – Ratio Charts 33
Section 4 – Company’s Lifesciences Financial Deals and Alliances 34
Spectrum Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 34
Spectrum Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 35
Spectrum Pharmaceuticals, Inc., Recent Deals Summary 36
Section 5 – Company’s Recent Developments 37
Mar 13, 2015: Spectrum Pharmaceuticals Reports Robust Clinical Data and Strong 2014 Financial Results 37
Nov 06, 2014: Spectrum Pharmaceuticals Reports Strong Product Sales for the Third Quarter 2014; Sales of $47.9 Million up 15.6% Over Last Year 39
Aug 07, 2014: Spectrum Pharmaceuticals Reports 45% Sales Growth in the Second Quarter, Launches Fifth Product and Moves Closer to a Decision on a Potential Blockbuster 40
May 08, 2014: Spectrum Pharmaceuticals Reports Financial Results for First Quarter 2014 41
Apr 21, 2014: Spectrum Pharmaceuticals Promotes and Appoints Joseph Turgeon as President and Chief Operating Officer 42
Mar 07, 2014: Spectrum Pharmaceuticals Reports Fourth and Full Year 2013 Financial Results 43
Section 6 – Appendix 45
Methodology 45
Ratio Definitions 45
About GlobalData 49
Contact Us 49
Disclaimer 49



List of Tables
Spectrum Pharmaceuticals, Inc., Key Facts 6
Spectrum Pharmaceuticals, Inc., Key Employees 7
Spectrum Pharmaceuticals, Inc., Key Employee Biographies 8
Spectrum Pharmaceuticals, Inc., Major Products and Services 9
Spectrum Pharmaceuticals, Inc., Number of Pipeline Products by Therapy Area 10
Spectrum Pharmaceuticals, Inc., Number of Pipeline Products by Development Stage 11
Spectrum Pharmaceuticals, Inc., Pipeline Products By Therapy Area and Development Phase 12
Spectrum Pharmaceuticals, Inc., History 14
Spectrum Pharmaceuticals, Inc., Other Locations 19
Spectrum Pharmaceuticals, Inc., Subsidiaries 19
Spectrum Pharmaceuticals, Inc., Key Competitors 27
Spectrum Pharmaceuticals, Inc., Ratios based on current share price 28
Spectrum Pharmaceuticals, Inc., Annual Ratios 29
Spectrum Pharmaceuticals, Inc., Interim Ratios 32
Spectrum Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 34
Spectrum Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2009 to YTD 2015 35
Spectrum Pharmaceuticals, Inc., Recent Deals Summary 36
Currency Codes 45
Capital Market Ratios 45
Equity Ratios 46
Profitability Ratios 46
Cost Ratios 47
Liquidity Ratios 47
Leverage Ratios 48
Efficiency Ratios 48



List of Figures
Spectrum Pharmaceuticals, Inc., Pipeline Products by Therapy Area 10
Spectrum Pharmaceuticals, Inc., Pipeline Products by Development Phase 11
Spectrum Pharmaceuticals, Inc., Performance Chart (2009 – 2013) 31
Spectrum Pharmaceuticals, Inc., Ratio Charts 33
Spectrum Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2009 to YTD 2015 34
Spectrum Pharmaceuticals, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2009 to YTD 2015 35

Report Delivery

PDF SWOT Analysis Report An Electronic PDF copy of this Report will be sent to you via email.

Please allow up to 2 business days for the reports to arrive to your mailbox as some of our publishers prefer to send you the reports directly.

Purchase this Report today

Price: $125

Report Licences Explanation

* Single User: Electronic PDF copy delivered via email. Report can be used by individual purchaser only.

* Site License: Electronic PDF copy delivered via email. Report can be shared by unlimited users within one corporate location, e.g. a regional office.

* Enterprise Wide License: Electronic PDF copy delivered via email. Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company.

If you require a Site License or Enterprise Wide License please contact us to issue you an invoice.

Customers who Viewed this Report also Viewed

Risk warning: Your capital may be at risk. CFD trading is suitable for experienced traders and not beginners.